Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/29/2019
Start Date:December 17, 2018
End Date:January 21, 2026
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given
prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or
without cisplatin), as post-surgical therapy in treatment naïve participants with newly
diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell
carcinoma (LA-HNSCC). The primary hypothesis is that pembrolizumab given before surgery and
after surgery in combination with radiotherapy (with or without cisplatin) improves major
pathological response and event-free survival compared to radiotherapy (with or without
cisplatin) alone.


Inclusion Criteria:

- Has histologically confirmed new diagnosis of resectable, non-metastatic, squamous
cell carcinoma that is either: Stage III Human Papillomavirus (HPV) positive
oropharyngeal primary that is tumor size (T) 4, lymph node involvement (N) 0-2, no
distant metastases (M0); Stage III or IVA oropharyngeal HPV negative; or Stage III or
IVA larynx/hypopharynx/oral cavity primaries

- Is eligible for primary surgery based on investigator decision and per local practice

- Female and male participants of reproductive potential must agree to use adequate
contraception throughout the study period and for up to 180 days after the last dose
of study therapy

- Male participants must refrain from donating sperm throughout the study period and for
up to 180 days after the last dose of study therapy

- Female participant that is not pregnant or breastfeeding

- Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed
by computed tomography (CT) scan or magnetic resonance imaging (MRI), based on RECIST
version 1.1

- Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated

- Has results from testing of HPV status for oropharyngeal cancer defined as p16

- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed
within 10 days prior to receiving the first dose of study therapy

Exclusion Criteria:

- Has Stage T4B and/or N3 LA HNSCC and/or distant metastases

- Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as
nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer
(HNC)

- Female participant who has a positive urine pregnancy test within 72 hours prior to
study start or within 24 hours prior to the start of radiotherapy with or without
cisplatin

- Has received prior therapy with an anti-programmed cell death receptor 1(PD-1),
anti-programmed cell death receptor ligand 1(PD-L1), or anti-programmed cell death
receptor ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory
T-cell receptor

- Has received prior radiotherapy treatment or systemic anti-cancer therapy including
investigational agents for the HNC under study prior to study start

- Has received a live vaccine within 30 days prior to the first dose of study therapy

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study therapy

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in
dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study therapy

- Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years with the exception of basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ (e.g. in situ cervical
cancer or breast carcinoma) that have undergone potentially curative therapy

- Has radiographically detectable (even if asymptomatic and/or previously treated)
central nervous system metastases and/or carcinomatous meningitis

- Has Grade ≥2 audiometric hearing loss

- Has Grade ≥2 neuropathy

- Has Grade 3-4 bleeding due to the underlying malignancy

- Has received major surgery or has not recovered adequately from the toxicity and/or
complications from the intervention prior to study start

- Has had previous allogeneic tissue/solid organ transplant

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients,
radiotherapy, cisplatin or their analogs

- Has an active autoimmune disease that has required systemic treatment in past 2 years

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis

- Has an active infection requiring systemic therapy

- Has a known history of human immunodeficiency virus (HIV) infection

- Has a known history of or is positive for Hepatitis B (defined as hepatitis B surface
antigen [HBsAg] reactive) or known active Hepatitis C (defined as Hepatitis C virus
[HCV] ribonucleic acid is detected).

- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the participant's
participation for the full duration of the study, or is not in the best interest of
the participant to participate, in the opinion of the investigator

- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study
We found this trial at
29
sites
2055 South Fremont Avenue
Springfield, Missouri 65804
Phone: 417-820-8099
?
mi
from
Springfield, MO
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Phone: 352-273-8008
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Phone: 503-215-5696
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Albuquerque, New Mexico 87131
Phone: 505-925-0366
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 720-848-0702
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Billings, Montana 59102
Phone: 406-238-6290
?
mi
from
Billings, MT
Click here to add this to my saved trials
1055 N Curtis Rd
Boise, Idaho 83706
(208) 367-2121
Phone: 208-367-3131
Saint Alphonsus Regional Medical Center Saint Alphonsus Health System is a four-hospital regional, faith-based Catholic...
?
mi
from
Boise, ID
Click here to add this to my saved trials
Charlotte, North Carolina 28211
Phone: 980-442-5217
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlottesville, Virginia 22908
Phone: 434-924-1904
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Phone: 214-648-6209
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Phone: 313-576-8994
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-1049
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Easton, Pennsylvania 18045
Phone: 484-503-4156
?
mi
from
Easton, PA
Click here to add this to my saved trials
?
mi
from
Edina, MN
Click here to add this to my saved trials
Evanston, Illinois
Phone: 847-570-2109
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fairfax, Virginia 22031
Phone: 703-207-0733
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
La Jolla, California 92093
Phone: 858-534-6161
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90033
Phone: 323-865-0421
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
160 East 34th Street
New York, New York 10016
Phone: 212-731-6465
?
mi
from
New York, NY
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Phone: 412-330-6129
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97227
Phone: 503-494-8666
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rosario,
Phone: +543414218909
?
mi
from
Rosario,
Click here to add this to my saved trials
Sacramento, California 95817
Phone: 916-734-8452
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-747-8378
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84112
Phone: 801-587-5562
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Santa Rosa, California 95403
Phone: 707-521-3836
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Phone: 605-328-1365
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Westwood, Kansas 66205
Phone: 913-588-6029
?
mi
from
Westwood, KS
Click here to add this to my saved trials
Worcester, Massachusetts 01655
Phone: 508-334-5539
?
mi
from
Worcester, MA
Click here to add this to my saved trials